Verastem Inc. (VSTM)

1.34
NASDAQ : Health Technology
Prev Close 1.31
Day Low/High 1.32 / 1.37
52 Wk Low/High 1.16 / 9.32
Avg Volume 1.57M
Exchange NASDAQ
Shares Outstanding 74.14M
Market Cap 97.12M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BOSC, NL Downgrades: AMCX, APOG, AXL, AZZ, BHB, DGICA, DGICB, KMT, PACW, SJR, TGS, VIAB Initiations: DOVA, VSTM Read on to get TheStreet Quant Ratings' detailed report:

Verastem Oncology Reports Second Quarter 2019 Financial Results And Highlights Recent Company Progress

Verastem Oncology Reports Second Quarter 2019 Financial Results And Highlights Recent Company Progress

Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology (or "the Company"), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today reported financial results for the three...

(Photo: Business Wire)

(Photo: Business Wire)

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Brian Stuglik, a...

Verastem Oncology Signs An Exclusive License Agreement With Sanofi For The Development And Commercialization Of COPIKTRA® (duvelisib) In Russia And CIS, Turkey, The Middle East And Africa

Verastem Oncology Signs An Exclusive License Agreement With Sanofi For The Development And Commercialization Of COPIKTRA® (duvelisib) In Russia And CIS, Turkey, The Middle East And Africa

Verastem, Inc. (NASDAQ: VSTM) operating as Verastem Oncology, (or "the Company"), today announced their entry into an exclusive licensing agreement with Sanofi to develop and commercialize Verastem Oncology's COPIKTRA ® (duvelisib), an oral inhibitor of...

Verastem Oncology To Announce Second Quarter 2019 Financial Results And Corporate Update On August 1, 2019

Verastem Oncology To Announce Second Quarter 2019 Financial Results And Corporate Update On August 1, 2019

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will...

Interesting VSTM Put And Call Options For March 2020

Interesting VSTM Put And Call Options For March 2020

Investors in Verastem Inc saw new options begin trading this week, for the March 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to...

Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data In Peripheral T-Cell Lymphoma At The 2019 International Conference On Malignant Lymphoma

Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data In Peripheral T-Cell Lymphoma At The 2019 International Conference On Malignant Lymphoma

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced an oral presentation...

Verastem Oncology Announces Leadership Changes

Verastem Oncology Announces Leadership Changes

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Robert Forrester...

Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data At The European Hematology Association 2019 Annual Meeting

Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data At The European Hematology Association 2019 Annual Meeting

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that two posters...

First Week Of July 19th Options Trading For Verastem (VSTM)

First Week Of July 19th Options Trading For Verastem (VSTM)

Investors in Verastem Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VSTM options chain for the new July 19th contracts and identified the following call contract of particular interest.

Verastem Oncology To Present At The Jefferies 2019 Global Healthcare Conference

Verastem Oncology To Present At The Jefferies 2019 Global Healthcare Conference

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the Jefferies...

Verastem Oncology To Present At The 20th Annual B. Riley FBR Institutional Investor Conference

Verastem Oncology To Present At The 20th Annual B. Riley FBR Institutional Investor Conference

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 20 th Annual...

Verastem Oncology To Present New COPIKTRA™ (Duvelisib) Dose Modification Data From Patients Treated In The Phase 3 DUO Study

Verastem Oncology To Present New COPIKTRA™ (Duvelisib) Dose Modification Data From Patients Treated In The Phase 3 DUO Study

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a poster highlighting...

Verastem Oncology Reports First Quarter 2019 Financial Results

Verastem Oncology Reports First Quarter 2019 Financial Results

Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology, (or "the Company"), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today reported financial results for the three...

Verastem Oncology To Announce First Quarter 2019 Financial Results And Corporate Update On May 9, 2019

Verastem Oncology To Announce First Quarter 2019 Financial Results And Corporate Update On May 9, 2019

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will...

First Week Of VSTM December 20th Options Trading

First Week Of VSTM December 20th Options Trading

Investors in Verastem Inc saw new options begin trading this week, for the December 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Verastem Oncology Announces Amendment To Refinance Hercules Loan Facility

Verastem Oncology Announces Amendment To Refinance Hercules Loan Facility

Verastem, Inc. (Nasdaq: VSTM) operating as Verastem Oncology, (or the "Company"), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced its entry into an amendment (the...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 112,000 shares of its...

Verastem Oncology To Present At The H.C. Wainwright Global Life Sciences Conference

Verastem Oncology To Present At The H.C. Wainwright Global Life Sciences Conference

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.

Verastem Oncology Announces Fourth Quarter And Full-Year 2018 Financial Results And Corporate Developments

Verastem Oncology Announces Fourth Quarter And Full-Year 2018 Financial Results And Corporate Developments

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, (or "the Company"), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today reported financial results for the three and twelve...

Verastem Oncology To Present At Upcoming Investor Conferences

Verastem Oncology To Present At Upcoming Investor Conferences

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will present at the following...

Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data At The 23rd Annual International Congress On Hematologic Malignancies

Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data At The 23rd Annual International Congress On Hematologic Malignancies

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that three COPIKTRA...

New 52-Week Low Could Prompt More Insider Buying At VSTM

New 52-Week Low Could Prompt More Insider Buying At VSTM

In trading on Thursday, shares of Verastem Inc touched a new 52-week low of $2.61/share. That's a $7.74 share price drop, or -74.78% decline from the 52-week high of $10.35 set back on 09/04/2018.

Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) In Patients With CLL/SLL Who Have Progressed Following Two Prior Lines Of Therapy

Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) In Patients With CLL/SLL Who Have Progressed Following Two Prior Lines Of Therapy

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a poster highlighting...

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of options to purchase 239,000 shares of its...

Verastem Oncology To Announce Fourth Quarter And Full-Year 2018 Financial Results And Corporate Update On March 12, 2019

Verastem Oncology To Announce Fourth Quarter And Full-Year 2018 Financial Results And Corporate Update On March 12, 2019

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will...

Verastem Oncology To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Verastem Oncology To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 8 th Annual SVB...

TheStreet Quant Rating: D- (Sell)